Equinor ASA vs Illumina, Inc. — how do they compare? Equinor ASA trades at $43 (market cap $101.62B), while Illumina, Inc. trades at $264.95 (market cap $39.95B). The key difference: Equinor ASA is far larger — about 2.5× Illumina, Inc.'s market cap, and Equinor ASA pays a 3.63% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Illumina, Inc. for 83 Days on average.
| EQNR | ILMN | |
|---|---|---|
Market Cap | $101.62B | $39.95B |
Volume | 4,991,782 | 3,169,503 |
Sector | Energy | Health |
52-Week High | $45.75 | $293.69 |
52-Week Low | $22.41 | $91.00 |
Typical Hold Time | 59 Days | 83 Days |
Enterprise Value | $110.31B | $41.31B |
Dividend Yield | 3.63% | — |
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $41.61, down 3.26% today, with a bearish technical signal despite strong valuation metrics including a P/E of 11.28 and EV/EBITDA of 2.35. The company has beaten earnings estimates in two of the last three quarters, with Q3 2026 results pending. Recent news highlights expansion in LNG and carbon capture projects, while cash flow trends show improving operational performance from 2025 levels.
EQNR presents a compelling value opportunity with significant upside to the $70.50 consensus price target, though near-term technical weakness and declining profit margins from 2022 peaks pose risks. The stock's 21.32% ROE and dividend payments support income investors, while LNG expansion plans provide growth catalysts. Market sentiment remains mixed with 30% buy ratings amid energy sector volatility.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →